|
Jan 28
|
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
|
|
Jan 28
|
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
|
|
Jan 27
|
MSD wins FDA priority review for Welireg in rare endocrine cancer
|